You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR DIETHYLCARBAMAZINE CITRATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for diethylcarbamazine citrate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01111305 ↗ Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2010-04-01 Diethylcarbamazine citrate (DEC) treatment of Loa loa infection is complicated by the development of severe adverse reactions that are correlated with the number of circulating microfilariae in the blood. The cause of these reactions is unknown, but they are accompanied by a dramatic interleukin-5 (IL-5)-dependent increase in eosinophilia and evidence of eosinophil activation. This randomized, placebo-controlled, double-blind pilot study (conducted at the NIH Clinical Center) will assess whether and to what extent the administration of reslizumab (Cinquil ), a humanized monoclonal antibody directed against IL-5, given 3 to 7 days before administration of the anthelminthic drug DEC (at 3 mg/kg 3 times daily for 21 days), prevents the development of eosinophilia in 10 adult subjects with Loa loa infection and 0-5000 microfilariae/mL. Secondary outcomes will include the severity of post-treatment effects, markers of eosinophil activation, and effects of reslizumab on microfilarial clearance.
NCT01593722 ↗ Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 4 2012-04-01 Background: - Loa loa is a small worm that infects people in West and Central Africa. It is spread by the bite of a fly. Adult worms live under the skin and can cause swelling in the arms, legs, and face. Some people have more serious infections in the heart, kidneys, or brain. Most people with Loa loa infection have no symptoms at all. The standard treatment for Loa loa infection is a medicine called diethylcarbamazine (DEC). Some people have bad reactions to DEC, including itching, muscle pains, and in severe cases coma and death. - Another drug, ivermectin, is used in mass drug treatment programs to prevent the spread of worm infections that cause blindness and massive swelling (elephantiasis). However, people who also have Loa loa have had serious bad reactions to ivermectin. Researchers want to study both DEC and ivermectin to find out why these reactions occur. If they can be prevented, mass drug treatment programs will be able to be used in areas in Africa where Loa loa exists. Objectives: - To study the side effects of DEC and ivermectin treatment for Loa loa infection. Eligibility: - Individuals who live in 4 villages in Cameroon where Loa loa infection is known to exist, who are between 20 and 60 years of age, not pregnant or breastfeeding and have a low level of Loa loa parasites in the blood, but are otherwise healthy. Design: - Participants will be screened with a physical exam and medical history. Blood samples will be collected to check for Loa loa infection. Participants will also have an eye exam and provide skin samples to check for other worm infections that may interfere with the study treatment. - Participants will be admitted to the hospital for 4 days (during and after the treatment). They will receive a single dose of either DEC or ivermectin. - After treatment, regular blood samples will be collected. Participants will be asked questions about how they feel after treatment. Physical exams will be performed. If side effects develop, participants will be treated at the hospital. - After leaving the hospital, participants will have followup visits. These visits will happen on days 5, 7, 9, and 14 after receiving the study medicine. They will involve a short physical exam and collection of blood samples. - At the end of the study, participants will be offered a full 21-day DEC treatment to cure the Loa loa infection.
NCT04410406 ↗ Moxidectin for LF, Cote d'Ivoire (DOLF) Enrolling by invitation Case Western Reserve University Phase 3 2020-08-20 The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).
NCT04410406 ↗ Moxidectin for LF, Cote d'Ivoire (DOLF) Enrolling by invitation Regional Hospital of Agboville, Southern Cote d'Ivoire Phase 3 2020-08-20 The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).
NCT04410406 ↗ Moxidectin for LF, Cote d'Ivoire (DOLF) Enrolling by invitation Washington University School of Medicine Phase 3 2020-08-20 The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for diethylcarbamazine citrate

Condition Name

Condition Name for diethylcarbamazine citrate
Intervention Trials
Loiasis 2
Lymphatic Filariasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for diethylcarbamazine citrate
Intervention Trials
Loiasis 2
Filariasis 1
Elephantiasis, Filarial 1
Elephantiasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for diethylcarbamazine citrate

Trials by Country

Trials by Country for diethylcarbamazine citrate
Location Trials
Cameroon 1
United States 1
Côte D'Ivoire 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for diethylcarbamazine citrate
Location Trials
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for diethylcarbamazine citrate

Clinical Trial Phase

Clinical Trial Phase for diethylcarbamazine citrate
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for diethylcarbamazine citrate
Clinical Trial Phase Trials
Completed 2
Enrolling by invitation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for diethylcarbamazine citrate

Sponsor Name

Sponsor Name for diethylcarbamazine citrate
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 2
Case Western Reserve University 1
Regional Hospital of Agboville, Southern Cote d'Ivoire 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for diethylcarbamazine citrate
Sponsor Trials
Other 3
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.